Ranbaxy downplays Toansa effect, claims FTF opportunities still hold
This article was originally published in Scrip
Executive Summary
A subdued Ranbaxy management on 5 February insisted that only 10-12% of the firm's US sales depended on active pharmaceutical ingredients (APIs) from that tainted Toansa site in India and that the company has, as part of its derisking strategy, ensured that it has more than one approved source for APIs for certain products.